Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) said CEO Mark A. Goldsmith, M.D., Ph.D., will take part in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.

According to the company, a live webcast will be available and a replay will remain on the company website for at least 14 days.

News Market Reaction – RVMD

-1.52%

3 alerts

-1.52% Session close to close

-8.1% Trough Tracked

$19.96B Market Cap

0.2x Rel. Volume

In the Feb 25 session, RVMD declined 1.52%, reflecting a mild negative market reaction. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds another investor-relations touchpoint, with RVMD’s CEO joining a fireside cha...

Analysis

This announcement adds another investor-relations touchpoint, with RVMD’s CEO joining a fireside chat at the TD Cowen health care conference on March 3 at 9:50 a.m. ET. It continues a pattern of conference participation and webcasts, complementing earlier clinical and regulatory milestones. Investors may watch for any new disclosures during the session and subsequent updates around upcoming earnings and ongoing RAS-focused clinical programs.

Key Figures

Conference edition: 46th Annual Conference date: March 3 Start time: 9:50 a.m. ET +1 more

4 metrics

Conference edition 46th Annual TD Cowen 46th Annual Health Care Conference

Conference date March 3 Date of TD Cowen conference fireside chat

Start time 9:50 a.m. ET Scheduled time for the TD Cowen conference fireside chat

Webcast replay window 14 days Replay available on company website after live webcast

Historical Context

5 past events · Latest: Feb 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 18	Earnings date notice	Neutral	-0.8%	Announcement of timing for Q4 and full-year 2025 results webcast.
Feb 4	Conference participation	Neutral	-0.4%	Fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
Jan 29	Clinical trial start	Positive	+0.9%	First patient dosed in trial of RMC-5127, a RAS(ON) G12V inhibitor.
Jan 8	FDA designation	Positive	+4.6%	FDA Breakthrough Therapy Designation for zoldonrasib in KRAS G12D NSCLC.
Jan 5	Conference presentation	Neutral	+1.9%	J.P. Morgan Healthcare Conference presentation and webcast replay details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news—especially clinical and regulatory milestones—has often been followed by modestly positive price reactions, while routine conference and scheduling updates have seen small moves in either direction.

Recent Company History

Over the last few months, RVMD has mixed routine investor-relations updates with notable clinical and regulatory milestones. On Jan 5, a J.P. Morgan conference presentation coincided with a 1.94% gain, followed by an FDA Breakthrough Therapy Designation on Jan 8 that saw shares rise 4.56%. The first‑patient dosing trial update on Jan 29 aligned with a 0.89% gain. In contrast, conference and earnings-date notices on Feb 4 and Feb 18 prompted only small moves (-0.37%, -0.82%), similar in nature to today’s conference participation news.

Key Terms

oncology, webcast

2 terms

oncology medical

"a late-stage clinical oncology company developing targeted therapies"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

webcast technical

"To listen to a live webcast of this event, or access an archived webcast"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET.

To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact: 
media@revmed.com
investors@revmed.com 

FAQ

When will Revolution Medicines (RVMD) present at the TD Cowen conference in 2026?

Revolution Medicines will present on March 3, 2026 at 9:50 a.m. ET. According to the company, CEO Mark A. Goldsmith will participate in a fireside chat; the session is part of TD Cowen's 46th Annual Health Care Conference.

How can investors watch Revolution Medicines (RVMD) at the March 3, 2026 TD Cowen event?

Investors can watch via a live webcast on the company's investor website. According to the company, the live webcast link is available at the events and presentations page and a replay will be posted afterward.

Will a replay of Revolution Medicines (RVMD) TD Cowen presentation be available after March 3, 2026?

Yes, a replay will be available for at least 14 days following the live webcast. According to the company, the archived webcast can be accessed on the company's investor events and presentations page.

Who from Revolution Medicines (RVMD) will speak at the TD Cowen 46th Annual Health Care Conference?

CEO and chairman Mark A. Goldsmith, M.D., Ph.D. will participate in the fireside chat. According to the company, he will represent Revolution Medicines during the March 3, 2026 session at TD Cowen.

What time is Revolution Medicines (RVMD) scheduled at the TD Cowen conference on March 3, 2026?

The company is scheduled for 9:50 a.m. ET on March 3, 2026. According to the company, this is the start time for the CEO's fireside chat at the TD Cowen 46th Annual Health Care Conference.

Where can I find the webcast and replay for Revolution Medicines (RVMD) TD Cowen presentation?

The webcast and replay are posted on the company's investor website under Events and Presentations. According to the company, the live webcast link and archived replay will be available on that page.